52 results about "Gastrin" patented technology

The invention belongs to the technical field of immunoassay and biosensing, and provides a preparation method of a photoelectrochemical sensor based on CuO-induced photocurrent polarity reversal. The invention provides a preparation method of the photoelectrochemical sensor based on CuO-induced photocurrent polarity reversal. Specifically, hollow polyhedral flower-shaped CuO with a unique inner cavity structure is adopted as a polarity induction factor, so that multiple light refraction and scattering effects are remarkably enhanced, and the light capture efficiency is improved. Besides, when CuO is introduced to the surface of the In2O3 / ZnCdS electrode as a photocurrent polarity reversal factor, due to the energy band structure difference between CuO and In2O3 / ZnCdS, the migration path of a photon-generated carrier is changed, and the photocurrent polarity is reversed from an anode to a cathode photocurrent, so that the detection specificity of the gastrin-releasing peptide is improved. The photocurrent polarity reversal strategy effectively eliminates potential false positive signal interference, and the accuracy and sensitivity of detection are remarkably improved. According to different photoelectrochemical signal intensities of to-be-detected substances with different concentrations, the gastrin-releasing peptide is detected.

The present invention rreellaatteess to gastrin-releasing peptide receptor (GRPR)-targeted compounds and their use for imaging and treatment of diseases or conditions characterized by expression of the gastrin-releasing peptide receptor.

There is provided peptidic compounds of Formula I, A or B(Rradn6-[linker]-RL-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-ψ-Xaa9-NH2). Xaa1 is D-Phe, Cpa, D-Cpa, Nal, D-Nal, 2-Nal, or D-2-Nal; Xaa2 is Asn, Gln, Hse, Cit or His. Xaa3 is Trp, Bta, Trp(Me), Trp(7-Me), Trp(6-Me), Trp(5-Me), Trp(4-Me), Trp(2-Me), Trp(7-F), Trp(6-F), Trp(5-F), Trp(4-F), Trp(5-OH), or αMe-Trp. Xaa4 is Ala or Ser. Xaa5 is Val, Cpg, or Tle. Xaa6 is Gly, NMe-Gly, or D-Ala. Xaa7 is His or NMe-His. Xaa8 is Leu or Phe. Xaa9-NH2 is a C-terminally amidated amino acid residue selected from Pro, 4-oxa-L-Pro, Me2Thz, or Thz. ψ represents a peptide bond or reduced peptide bond joining Xaa8 to Xaa9. Rradn6 is 1-5 radiolabeling groups. There is also provided the use of such compounds as imaging agents or therapeutic agents.

The application provides a culture medium and a culture method of ovarian cancer primary cells. The culture medium comprises an MST1 / 2 kinase inhibitor, sodium pyruvate, forskolin, epidermal growth factor, gastrin, fibroblast growth factor 7, nicotinamide, SB431542, and fetal bovine serum. Compared with the existing culture method, the in-vitro culture using the culture medium of the application has higher amplification efficiency; the culture of the ovarian cancer primary cells using the culture medium can maintain the morphological structure and pathological characteristics of the primary tissue, and improve the success rate and survival rate of the ovarian cancer primary cell culture.

To provide a radionuclide complex solution of high concentration and high chemical stability which can be used as a medicine for diagnosis and / or treatment.SOLUTION: Provided is a pharmaceutical composition comprising: (a) a complex formed by: (ai) a radionuclide; and (aii) a gastrin releasing peptide receptor peptide antagonist binding moiety linked to a chelating agent; (b) at least two stabilizers against radiolysis; and (c) optionally a surfactant.SELECTED DRAWING: None

The present application relates to compounds of formula (I) or (Ia) (e.g., fexuprazan), for treating pathological hypersecretory conditions, such as a condition comprising gastric acid hypersecretion (e.g., Zollinger-Ellison syndrome, idiopathic gastric acid hypersecretion, and / or hypergastrinemia).

The invention provides an organoid culture medium, an organoid culture method and application of the organoid culture medium, the organoid culture medium comprises a first-stage culture medium, the first-stage culture medium comprises a first-stage basic culture medium and first-stage addition factors, and the first-stage addition factors comprise N-acetylcysteine, nicotinamide, a ROCK inhibitor, Noggin, R-spondin, EGF, HGF, Gastrin, FGF10, Blebbistatin, Forskolin, A83-01, LDN193189, DAPT, TGF-alpha and UDAC. By using the organoid culture medium, the liver organoid and the fatty liver organoid can be effectively obtained, and the obtained fatty liver organoid has obvious fat deposition, is sensitive to fatty liver treatment drugs, highly restores the physiological status when human body fatty liver diseases occur, and has high application value.

The present invention provides a culture medium for primary ovarian cancer cells, an in vitro culture method, and applications thereof. The culture medium comprises an MST1 / 2 kinase inhibitor; at least one Rho protein kinase inhibitor selected from Y27632, fasudil, and H-1152; an insulin-transferrin-selenium supplement; insulin; prostaglandin E2; epidermal growth factor; gastrin; insulin-like growth factor-1; cholera toxin; amphiregulin; N2; and B27. Compared to existing culture methods, in vitro culture using the culture medium of the present invention has higher expansion efficiency. Culturing primary ovarian cancer cells using this culture medium can maintain the morphological structure and pathological characteristics of the primary tissue, thereby improving the success rate and survival rate of primary ovarian cancer cell culture.

The invention discloses an external composition which contains a traditional Chinese medicine composition, and the traditional Chinese medicine composition comprises fructus cnidii, radix sophorae flavescentis and cortex dictamni. The external composition can be applied to preparation of a regulating agent for regulating and controlling the reduction of the concentration of neuropeptide and / or histamine in blood. The external composition can act on a skin target area where pruritus occurs, the concentration of P substances, gastrin releasing peptide and histamine in blood can be regulated and controlled, and then the attack of symptoms such as pruritus and the like can be relieved or treated.

The present invention provides a culture medium for culturing primary gastric cancer cells, comprising an MST1 / 2 kinase inhibitor, a ROCK kinase inhibitor, at least one of a B27 additive and an N2 additive, basic fibroblast growth factor, CHIR99021, epidermal growth factor, an ITS cell culture additive, SB202190, dexamethasone, fibroblast growth factor 10, N-acetyl-L-cysteine, and gastrin. The present invention also relates to a culture method using the primary cell culture medium, wherein the culture medium is used to culture the primary cells on a culture vessel coated with extracellular matrix glue, thereby rapidly proliferating the primary cells.

There is provided peptidic compounds of Formula I, A or B(Rradn6-[linker]-RL-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-ψ-Xaa9-NH2). Xaa1 is D-Phe, Cpa, D-Cpa, Nal, D-Nal, 2-Nal, or D-2-Nal; Xaa2 is Asn, Gln, Hse, Cit or His. Xaa3 is Trp, Bta, Trp(Me), Trp(7-Me), Trp(6-Me), Trp(5-Me), Trp(4-Me), Trp(2-Me), Trp(7-F), Trp(6-F), Trp(5-F), Trp(4-F), Trp(5-OH), or αMe-Trp. Xaa4 is Ala or Ser. Xaa5 is Val, Cpg, or Tle. Xaa6 is Gly, NMe-Gly, or D-Ala. Xaa7 is His or NMe-His. Xaa8 is Leu or Phe. Xaa9-NH2 is a C-terminally amidated amino acid residue selected from Pro, 4-oxa-L-Pro, Me2Thz, or Thz. ψ represents a peptide bond or reduced peptide bond joining Xaa8 to Xaa9. Rradn6 is 1-5 radiolabeling groups. There is also provided the use of such compounds as imaging agents or therapeutic agents.

The present application belongs to the technical field of protein short peptide, and discloses a gastrin releasing peptide precursor specific binding short peptide and application. The gastrin releasing peptide precursor is a tumor marker with high specificity and sensitivity, and plays an important role in early diagnosis, curative effect monitoring and prognosis judgment of non-small cell lung cancer. The present application obtains a gastrin releasing peptide precursor short peptide P2 through phage display technology, and the amino acid sequence is shown as SEQ ID NO. 1. The specific short peptide screened by the present application has the characteristics of small relative molecular mass and high affinity, and thus a probe can be designed for detecting the gastrin releasing peptide precursor, thereby providing a new direction for early diagnosis of tumors and research and development of targeted drugs in clinic.

The present invention provides a primary cell culture medium for culturing primary lung cancer epithelial cells, comprising an MST1 / 2 kinase inhibitor, a ROCK kinase inhibitor, a fibroblast growth factor, at least one additive selected from the group consisting of a B27 additive and an N2 additive, epidermal growth factor, transferrin, gastrin, and a TGFβ type I receptor inhibitor. The present invention also relates to a culture method using the primary cell culture medium and its use in drug efficacy evaluation and screening. The culture method uses the primary cell culture medium to culture primary lung cancer cells on a culture vessel coated with extracellular matrix gel, resulting in rapid proliferation of the primary lung cancer cells. The cell model obtained using the primary cell culture medium and primary cell culture method of the present invention can be used for drug efficacy evaluation and screening.

The present invention relates to the field of probiotics, in particular to an Akkermansia muciniphila MG784 for alleviating constipation, promoting defecation, improving intestinal barrier function and intestinal immunity, and its uses. The Akkermansia muciniphila MG784 provided by the present invention has the deposition number DSM 35549. The Akkermansia muciniphila MG784 provided by the present invention can increase the levels of motilin (MTL), gastrin (GAS), and acetylcholine in the gastrointestinal tract, promote intestinal peristalsis, improve the small intestine propulsion rate, and ameliorate defecation time and fecal output. Furthermore, Akkermansia muciniphila MG784 can also alleviate colonic mucosal inflammation, improve the thickness of the digestive tract muscular layer, modulate the structure of the intestinal microbiota, significantly increase the abundance of beneficial bacteria, and decrease the abundance of harmful bacteria.

The application provides a culture medium and a culture method of a gastric cancer organoid. The culture medium comprises an MST1 / 2 kinase inhibitor, a fibroblast growth factor 7, R-spondin 1, hydrocortisone, a B27 supplement, an N2 supplement, insulin, a dual regulatory protein, at least one Rho protein kinase inhibitor selected from Y27632, fasudil and H-1152, forskolin, gastrin, fetal bovine serum and cholera toxin. Compared with the existing culture method, the in-vitro culture using the culture medium has higher amplification efficiency; the culture of the gastric cancer organoid using the culture medium can maintain the morphological structure and pathological characteristics of the primary tissue, and improve the success rate and survival rate of the gastric cancer organoid culture.

A composition contains (i) rapamycin and / or a rapalog and (ii) a radiolabeled gastrin analogue. The composition can be used for the treatment and / or diagnosis of CCKB receptor positive cancer or tumors and leads to superior tumor uptake of radiolabeled gastrin analogue, resulting in improved delivery and therapeutic efficacy while cytotoxic side-effects are prevented and / or reduced.

The invention discloses a culture medium, and a culture method and a construction method of an organoid, and belongs to the technical field of organoids. The culture medium comprises a basic culture medium and gastrin with the final concentration of 2-4mg / L. In addition, the invention also provides a culture method of the organoid, which comprises the following steps: mixing tissue cells with matrigel, resuspending, inoculating, carrying out solidification treatment, and culturing in the culture medium to obtain the organoid. In addition, the invention also provides a construction method of the organoid, which comprises the following steps: transferring the organoid cultured by the culture method of the organoid for 2-4 generations to obtain an organoid library. The culture medium provided by the invention can be used for efficiently culturing the gastric cancer organs.

The utility model discloses a kind of mixing equipment of gastrin 17 detection reagent, including mixing shell, the top wall of the mixing shell is provided with feed pipe, further including mixing mechanism;Mixing mechanism: it includes driving shaft, connecting rod, outer stirrer, pivot, inner stirrer and transmission assembly, the mixing equipment of this gastrin 17 detection reagent, multiple operation is driven by primary, by outer stirring component rotation around device vertical axis, to mix uniform stirring to the mixing equipment raw material of gastrin 17 detection reagent at the edge of device internal wall body, by inner stirring component rotation around device horizontal horizontal axis, to mix uniform stirring to the mixing equipment raw material of gastrin 17 detection reagent at the central part of device inside, while the mixing equipment raw material of gastrin 17 detection reagent between two groups of stirring components is mutually crossed collision mixing, effectively improve the mixing efficiency of device to the mixing equipment raw material of gastrin 17 detection reagent.

The invention relates to the technical field of early gastric cancer screening, and discloses a novel biomarker detection method for early gastric cancer screening, which comprises the following steps: S1, preparation before detection: performing joint detection on pepsinogen, gastritin-17, carcino-embryonic antigen and carbohydrate antigen 72-4, and preparing corresponding detection reagents and standard substances; s2, sample collection: adopting a disposable sterile blood taking needle and a vacuum tube, and extracting 3-5ml of venous blood through sterile operation; s3, sample treatment and storage: separating serum through a centrifugal machine, and after the treatment is completed, putting the sample into a storage device for storage; and S4, detection operation: preheating the detector, and then calibrating the detector by a standard product. In the invention, the pepsinogen, the gastritin-17, the carcino-embryonic antigen and the carbohydrate antigen 72-4 are jointly detected, so that the problem of low accuracy possibly caused by the fact that a marker detection method is mostly adopted in the existing early gastric cancer screening is solved.

The application discloses a culture medium for constructing a gastric cancer ovary metastasis microtumor model and application. The application relates to the technical field of biotechnology, and provides a culture medium for constructing a gastric cancer ovary metastasis microtumor model, which is composed of three antibacterial and antifungal agents, HEPES, GlutaMax, human recombinant protein EGF, bFGF, HGF, FGF-10, Wnt-3a, Noggin, R-spondin 1, Follistatin, CHIR99021, SB202190, A83-01, Primocin, N-acetyl-L-cysteine, nicotinamide, N2 additives, cholera toxin, B27, ITS-X, Y-27632, gastrin, prostaglandin E2, beta-estradiol, progesterone, Galunisertib and a basic culture medium. The culture success rate of the gastric cancer ovary metastasis microtumor model is effectively improved.

The present application relates to the technical field of electrochemiluminescence immunoassay, and discloses a preparation for detecting progastrin-releasing peptide and application thereof, which contains a phosphate buffer, an alkali metal inorganic salt, bovine serum albumin, a preservative, a first surfactant and a second surfactant. The preparation has good universality and can be used for the preparation of monoclonal antibody coated magnetic microspheres and a working solution of a ruthenium compound labeled monoclonal antibody. The preparation can not only enhance the luminescence signal intensity of the reagent, but also ensure the stable performance of the reagent during long-term storage, thereby effectively enhancing the clinical applicability of the detection system and the reliability of the detection result.

The present invention relates to gastrin-releasing peptide receptor (GRPR)-targeted compounds and their use for imaging and treatment of diseases or conditions characterized by expression of the gastrin-releasing peptide receptor.

Provided are methods for preventing initiation and / or progression of gastrin-associated tumors and / or cancers in subjects. In some embodiments, the methods relate to administering compositions that gastrin immunogens to subjects. Also provided are methods for inhibiting development of gastrin-associated precancerous lesions, methods for preventing formation of fibrosis associated with a tumor and / or a cancer, uses of compositions that include a gastrin immunogen to prevent initiation and / or development of a gastrin-associated tumor or cancer and / or for preparing medicaments therefor, and compositions for use in preventing initiation and / or development of gastrin-associated tumors and / or cancers and / or precancerous lesions thereof.

The invention provides a multisystem disease analysis method based on gastrin plasma proteomics, which comprises the following steps of: A, analyzing a large number of adult individuals subjected to baseline evaluation by using queue research data of a biological sample library, and measuring a plurality of plasma proteins; b, analyzing a standardized protein expression (NPX) value of gastrin (GAST) by adopting a multivariable Cox proportional risk model, and correcting by using Bonferroni so as to reduce a false positive result; and C, exploring the correlation between the GAST-PRS and the disease phenotype by adopting full phenotype correlation analysis (PheWAS) based on polygene risk score (PRS), and further analyzing the genetic correlation between the GAST and the disease by using linkage imbalance score regression (LDSC). According to the method, the GAST can be redefined as a cross-system risk regulation factor, and the method is of great significance to layering of patients with shared pathway imbalance. The GAST has multi-system correlation with morbidity and mortality in the outcome of 168 diseases, and challenges the classical normal form of the gastrointestinal specific function of the GAST. These findings establish the location of GAST as a multi-system risk indicator.

The present invention relates to gastrin-releasing peptide receptor (GRPR)-targeted compounds and their use for imaging and treatment of diseases or conditions characterized by expression of the gastrin-releasing peptide receptor.

The invention discloses a composition for constructing an IOPN organ model, a model construction method and application. The composition for constructing the IOPN organoid model comprises an organoid model culture medium, and the organoid model culture medium comprises a penicillin-streptomycin double antibody solution, GlutaMAX, a serum-free supplement, Rspo-1, a Wnt activator, a growth factor, an HEPES buffer solution, N-acetyl-L-cysteine, a gastrin hormone, nicotinamide, forskolin, an ALK inhibitor, a ROCK inhibitor and the balance of a basic culture medium. The IOPN type organ model cultured by the composition for constructing the IOPN type organ model can maintain the original characteristics of tumors, provides a reliable biological model for pathological research and drug research and development of pancreatic tumors, and is convenient to operate and low in cost.

The invention discloses an amino acid and enzyme preparation nutrient mixture for promoting proliferation of gastrointestinal cells of dogs, and belongs to the technical field of pet food. According to the invention, the proliferation of intestinal epithelial cells and the secretion of Gastrin can be effectively promoted by supplementing arginine. In order to enhance the functional effect of the invention, lactase is especially added in the invention. On the basis of normal diet, 0.125%-0.5% of arginine and 0.00375%-0.015% of lactase are complementarily fed every day. The digestion and absorption of the dogs on nutrient substances of staple food grains can be improved, the parasitic quantity of intestinal escherichia coli of the dogs can be reduced, and excrement in a healthy form can be formed. In addition, the nutritional mixture can significantly promote the expression of epidermal growth factors (EGF). The invention discloses a mechanism for promoting proliferation of canine intestinal epithelial cells by arginine and lactase, and provides a new thought for prevention and treatment of canine digestive diseases.

Described herein are gastrin releasing peptide receptor (GRPR) binding peptide ligands having the formula: R1-R2-R3-(Q)-Z; wherein R1 is absent or is a chelator moiety, optionally chelated to a radioactive atom moiety; R2 is absent or is a linker; R3 is selected from the group consisting of an amino acid sequence having between 1-5 amino acids, or is absent; "Q" is a cyclic peptide sequence having between 4-7 amino acids; "Z" is a linear peptide sequence having between 4- 8 amino acids. Described herein are exemplary GRPR-binding peptide ligands and methods for diagnosis and treatment using them, in particular in relation to various types of cancer associated with GRPR expression.

The invention belongs to the technical field of biomedicine, and particularly discloses a gastrin-releasing peptide precursor determination kit and application, the gastrin-releasing peptide precursor determination kit comprises an anti-reagent A and an anti-reagent B; according to the invention, the antibody is labeled by the enhanced nano material, the detection sensitivity is obviously improved by the signal amplification effect, and the detection limit can be effectively detected.

The present invention relates generally to the identification and / or treatment of cancer, particularly cancers in which the gastrin-releasing peptide receptor (GRPR) is expressed. In particular embodiments, the present invention relates to the identification and / or treatment of prostate cancer, particularly GRPR-expressing metastatic castration-resistant prostate cancer.